Orlistat in the long-term treatment of obesity in primary care settings

Archives of Family Medicine

Volumn 9, Issue 2, 2000, Pages 160-167

  Hauptman, J ^a   Lucas, C ^a   Boldrin, M N ^a   Collins, H ^a   Segal, K R ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0033829586     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.9.2.160     Document Type: Article

References (32)

1. Overweight and obesity in the United States: Prevalence and trends, 1960-1994
2. Body weight and mortality among women
3. Actual causes of death in the United States
4. American Heart Association call to action: Obesity as a major risk factor for coronary heart disease
5. Hazards of obesity: The Framingham experience
6. Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis
7. Beneficial health effects of modest weight loss
8. Health consequences of therapeutic weight loss: Reducing primary risk factors
9. Prospective study of intentional weight loss and mortality in never-smoking US white women aged 40-64 years
10. Diet, behavior modification and exercise: A review of obesity treatments from a long-term perspective
11. Methods for voluntary weight loss and control
12. Lifestyle intervention in over-weight individuals with a family history of diabetes
13. Pharmacotherapy for obesity: Do the benefits outweigh the risks?
14. Evidence for success of caloric restriction in weight loss and control: Summary of data from industry
15. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers
16. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin)
17. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study
18. First clinical studies with orlistat: A short review
19. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
20. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study
21. Intent-to-treat analysis for longitudinal studies with drop-outs
22. Improving the quality of reporting of randomized controlled trials: The CONSORT statement
23. Design and analysis of obesity treatment and prevention trials
24. International trial of long-term dexfenfluramine in obesity
25. Long-term weight control study, IV (weeks 156-190): The second double-blind phase
26. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial JAMA
27. Pharmacotherapy for obesity
28. What is a reasonable weight loss? patients' expectations and evaluations of obesity treatment outcomes
29. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers
30. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers